Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PASSPORT)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy

The Primary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) at Week 52 and to assess the safety and tolerability of BIIB092, relative to placebo, by measuring the frequency of deaths, SAEs, AEs leading to discontinuation, and Grade 3 & 4 laboratory abnormalities.

The Secondary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change in baseline in the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II at Week 52, to evaluate the efficacy of BIIB092, compared to placebo, as measured by the Clinical Global Impression of Change (CGI-C) at Week 52, to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change in baseline in the Repeatable Battery for the Assessment of Neuropsychological Disease Severity (RBANS) at Week 52 and to assess the impact of BIIB092 on quality of life, relative to placebo, as measured by change from baseline on the Progressive Supranuclear Palsy Quality of Life scale (PSP-QoL) at Week 52.

Study Overview

• Status: Terminated
• Conditions: Supranuclear Palsy, Progressive
• Intervention / Treatment: Drug: BIIB092; Drug: Placebo

Detailed Description

This study, previously posted by Bristol-Myers Squibb, has transitioned to Biogen under a licensing agreement.

• Study Type: Interventional
• Enrollment (Actual): 490
• Phase: Phase 2

Contacts and Locations

Study Locations

• Australia
  • Victoria
    • North Melbourne, Victoria, Australia
      • Research Site
• Austria
  • Vienna, Austria
    • Research Site
  • Tirol
    • Innsbruck, Tirol, Austria
      • Research Site
• Canada
  • Ontario
    • London, Ontario, Canada
      • Research Site
    • Ottawa, Ontario, Canada
      • Research Site
    • Toronto, Ontario, Canada
      • Research Site
• France
  • Bordeaux, France
    • Research Site
  • Lille, France
    • Research Site
  • Marseille, France
    • Research Site
  • Nimes, France
    • Research Site
  • Paris, France
    • Research Site
  • Rennes, France
    • Research Site
  • Toulouse, France
    • Research Site
• Germany
  • Beelitz-Heilstatten, Germany
    • Research Site
  • Bochum, Germany
    • Research Site
  • Bonn, Germany
    • Research Site
  • Essen, Germany
    • Research Site
  • Kassel, Germany
    • Research Site
  • Ulm, Germany
    • Research Site
  • Bavaria
    • Munich, Bavaria, Germany
      • Research Site
  • Hessen
    • Marburg, Hessen, Germany
      • Research Site
  • Mecklenburg-Western-Pommerania
    • Rostock, Mecklenburg-Western-Pommerania, Germany
      • Research Site
  • North Rhine-Westphalia
    • Dusseldorf, North Rhine-Westphalia, Germany
      • Research Site
  • Sachsen
    • Dresden, Sachsen, Germany
      • Research Site
  • Schleswig-Holstein
    • Kiel, Schleswig-Holstein, Germany
      • Research Site
    • Luebeck, Schleswig-Holstein, Germany
      • Research Site
• Greece
  • Marousi
    • Athens, Marousi, Greece
      • Research Site
• Italy
  • Pisa, Italy
    • Research Site
  • Venice Lido, Italy
    • Research Site
  • Campania
    • Salerno, Campania, Italy
      • Research Site
• Japan
  • Shizuoka, Japan
    • Research Site
  • Aichi
    • Nagoya, Aichi, Japan
      • Research Site
  • Chiba
    • Kamagaya, Chiba, Japan
      • Research Site
  • Hokkaido
    • Sapporo, Hokkaido, Japan
      • Research Site
  • Kanagawa
    • Sagamihara, Kanagawa, Japan
      • Research Site
  • Tokyo
    • Kodaira, Tokyo, Japan
      • Research Site
  • Tottori
    • Yonago, Tottori, Japan
      • Research Site
• Korea, Republic of
  • Seoul, Korea, Republic of
    • Research Site
• Russian Federation
  • Krasnoyarsk, Russian Federation
    • Research Site
  • Moscow, Russian Federation
    • Research Site
• Spain
  • Barcelona, Spain
    • Research Site
  • Madrid, Spain
    • Research Site
  • Sevilla, Spain
    • Research Site
  • Valencia, Spain
    • Research Site
  • Navarra
    • Pamplona, Navarra, Spain
      • Research Site
  • Vizcaya
    • Barakaldo, Vizcaya, Spain
      • Research Site
• United Kingdom
  • London, United Kingdom
    • Research Site
  • Cambridgeshire
    • Cambridge, Cambridgeshire, United Kingdom
      • Research Site
  • East Sussex
    • Brighton, East Sussex, United Kingdom
      • Research Site
  • Hampshire
    • Southampton, Hampshire, United Kingdom
      • Research Site
  • Merseyside
    • Liverpool, Merseyside, United Kingdom
      • Research Site
  • Tyne And Wear
    • Newcastle Upon Tyne, Tyne And Wear, United Kingdom
      • Research Site
  • Wales
    • Newport, Wales, United Kingdom
      • Research Site
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85013
      • Research Site
    • Scottsdale, Arizona, United States, 85259
      • Research Site
    • Sun City, Arizona, United States, 85351
      • Research Site
  • California
    • Fountain Valley, California, United States, 92708
      • Research Site
    • La Jolla, California, United States, 92037
      • Research Site
    • Los Angeles, California, United States, 90095
      • Research Site
    • San Francisco, California, United States, 94158
      • Research Site
  • Florida
    • Boca Raton, Florida, United States, 33486
      • Research Site
    • Gainesville, Florida, United States, 32607
      • Research Site
    • Tampa, Florida, United States, 33612-4742
      • Research Site
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Research Site
    • Chicago, Illinois, United States, 60612-3841
      • Research name
    • Chicago, Illinois, United States, 60637-1447
      • Research Site
  • Indiana
    • Indianapolis, Indiana, United States, 46202-2280
      • Research Site
  • Kansas
    • Kansas City, Kansas, United States, 66160
      • Research Site
  • Louisiana
    • New Orleans, Louisiana, United States, 70121-2429
      • Research Site
  • Maryland
    • Baltimore, Maryland, United States, 21201
      • Research Site
    • Baltimore, Maryland, United States, 21287
      • Research Site
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Research Site
    • Burlington, Massachusetts, United States, 01702
      • Research Site
  • Michigan
    • Farmington Hills, Michigan, United States, 48334
      • Research Site
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455-0341
      • Research Site
  • New Jersey
    • New Brunswick, New Jersey, United States, 08901
      • Research Site
  • New York
    • Albany, New York, United States, 12208
      • Research Site
    • New York, New York, United States, 10029
      • Research Site
    • New York, New York, United States, 100029
      • Research Site
    • New York, New York, United States, 10032-3725
      • Research Site
  • Pennsylvania
    • Hershey, Pennsylvania, United States, 17033
      • Research Site
    • Philadelphia, Pennsylvania, United States, 19104
      • Research Site
  • South Carolina
    • Charleston, South Carolina, United States, 29425
      • Research Site
  • Texas
    • Dallas, Texas, United States, 75390-8869
      • Research Site
  • Virginia
    • Charlottesville, Virginia, United States, 22908-0394
      • Research Site
  • Washington
    • Seattle, Washington, United States, 98122
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 41 years to 86 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

• Participants with probable or possible PSP
• Able to ambulate independently or with assistance
• Able to tolerate MRI
• Have reliable caregiver to accompany participant to all study visits
• Score greater or equal to 20 on the Mini Mental State Exam (MMSE) at screening
• Participant must reside outside a skilled nursing facility or dementia care facility at the time of screening and admission to such a facility must not be planned

Key Exclusion Criteria:

• Presence of other significant neurological or psychiatric disorders
• Diagnosis of amyotrophic lateral sclerosis (ALS) or other motor neuron disease
• History of early, prominent rapid eye movement (REM) sleep behavior disorder
• History of or screening brain MRI scan indicative of significant abnormality
• Known history of serum or plasma progranulin level less than one standard deviation below the normal patient mean for the laboratory performing the assay

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BIIB092; Participants will receive BIIB092 50 mg/ml intravenous (IV) infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.	Drug: BIIB092; BIIB092 intravenous infusion on specified days; Other Names: BMS-986168
Placebo Comparator: Placebo; Participants will receive BIIB092 matching placebo IV infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.	Drug: Placebo; Placebo intravenous infusion on specified days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Progressive Supranuclear Palsy Rating Scale (PSPRS) at Week 52	The PSPRS is a quantitative measure of disability in participants with PSP. The PSPRS comprises 28 items in 6 areas. Six items are rated on a 3-point scale (0-2) and 22 are rated on a 5-point scale (0-4). The 6 areas are the History/Daily Activities, Mentation, Bulbar, Ocular Motor, Limb Motor, and Gait. The 28-item PSPRS total score ranges from 0 (normal) to 100. Fifteen items are selected to form a 15-item PSPRS and three domains are identified: Gait/Limb function, Ocular Motor, and Bulbar. The total 15-item PSPRS score ranges from 0 (normal) to 52. A positive change from baseline indicates worsening.	Baseline, Week 52
Percentage of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) and Adverse Events (AEs) Leading to Discontinuation of Drug	AEs: any sign, symptom, or diagnosis/disease that is unfavorable or unintended, that is new, or if pre-existing, worsens in participants administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. SAEs: an event that results in death; an event that, in the view of the investigator, places the participant at immediate risk of death (a life-threatening event); an outcome that results in a congenital anomaly/birth defect diagnosed in a child of a participant; an event that requires or prolongs inpatient hospitalization; an event that results in persistent or significant disability/incapacity.	up to 52 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Movement Disorder Society (MDS)-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II at Week 52	The MDS-UPRDRS Part 2 includes 13 items assessing motor aspects of experiences of daily living (M-EDL) these include speech, saliva and drooling, chewing and swallowing, handwriting, doing hobbies and other activities, eating tasks, tremor, dressing, hygiene, turning in bed, getting out of bed, walking and balance, and freezing. All items have 5 responses with uniform anchors of 0= normal, 1= slight, 2= mild, 3= moderate, and 4= severe. Total score ranges from 0 to 52, higher score indicating severe conditions. A positive change from baseline indicates worsening.	Baseline, Week 52
Clinical Global Impression of Change (CGI-C) Scale Score	The CGI-C scale measures the change in the patient's clinical status from a specific point in time. Using a 7-point scale, ranging from 1 (very much improved) to 7 (very much worse), with a score of 4 indicating no change.	Week 52
Change From Baseline in Progressive Supranuclear Palsy (PSP)-Cognitive Composite Battery Z-Score at Week 52	The PSP cognitive composite battery is used to identify and characterize abnormal cognitive decline in PSP participants. The PSP cognitive composite battery includes 13 sub-tests in total: 11 tests from the RBANS (only the picture naming is excluded), letter number sequencing test, and phonemic fluency test. Three domains are identified: Memory and learning, Visual-Motor function, and Working memory and Executive. A z-score transformation is applied for each component test at each visit, and the final total composite z-score is the average of the three-domain z-scores. A z-score of 0 is equal to the estimated mean adjusted by age and is considered average for this study population. Lower values are indicative of cognitive decline. A negative change from baseline indicates worsening.	Baseline, Week 52
Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Disease Severity (RBANS) Scale at Week 52	The RBANS provides both a total scale score and scores for 5 different cognitive domains. Specifically, the test measures immediate memory, visuospatial/constructional ability, language, attention, and delayed memory. Scores from all subtests are aggregated into a total composite score. RBANS data were age-normed and analyzed as index scores (also referred to as standard scores), which have a mean of 100 and a standard deviation of 15. Higher scores on each sub measure and index indicate better performance. A negative change from baseline indicates worsening.	Baseline, Week 52
Change From Baseline in Progressive Supranuclear Palsy Quality of Life Scale (PSP-QoL) Score	The PSP-QoL is a patient-reported outcome measure developed specifically for assessing the health-related quality of life in people living with PSP. It is validated 45-item questionnaire and visual analog scale that is comprised of 2 subscales: physical health state (22 items), which covers mobility, dysarthria, dysphagia, visual disturbances, self-care, and activities of daily living, and mental health state (23 items), which covers emotional, cognitive and social functioning. Items are given a 6-reponse option format (No Problem, Slight Problem, Moderate Problem, Marked Problem, Extreme Problem and Not Applicable). The subscale results are derived by summing the respective items for that subscale and transforming the scores into a range of 0 to 100, the higher the scores indicating a greater impact of the disease on the aspect measured. The PSP-QoL also comprises of a Life Satisfaction rating gauge, which is a visual analog scale with a range of 0 (worst) to 100 (best).	Baseline, Week 52
Change From Baseline in Schwab and England Activities of Daily Living (SEADL) Scale Score at Week 48	The SEADL scale is a means of assessing a person's ability to perform daily activities in terms of speed and independence, with 100% indicating total independence, falling to 0%, which indicates a state of complete dependence. The individual is asked to rate his or her function using an 11-point scale (10% increments), from 100% (completely independent; able to do all chores without slowness, difficulty, or impairment; essentially normal; unaware of any difficulty) to 0% (vegetative functions such as swallowing, bladder and bowels are not functioning; bedridden). A negative change from baseline indicates worsening.	Baseline, Week 48
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at Week 52	The Clinical Global Impression of Severity (CGI-S) Rating evaluates the severity of individual symptoms and treatment response in participants with mental disorders. The CGI-S is a 7-point scale that that requires the clinician to rate the severity of the patient's illness at the time of assessment. A rating of 1 is considered normal, or with the least severe symptoms, a rating of 7 is extremely ill, or the worst symptoms.	Baseline, Week 52
Change From Baseline in Phonemic Fluency Test Score at Week 48	Phonemic fluency is a sensitive test for assessing frontal lobe dysfunction. Participants are given a letter of the alphabet and asked to name as many words as they can that start with that letter in 1 minute. The score for each trial is auto-calculated as follows: Trial 1: Total number of correct responses for the first letter (range 0 to 40); Trial 2: Total number of correct responses for the second letter (range 0 to 40). The total score from the two trials will be used for analysis (range 0 to 80). More number of words correlates to better phonemic fluency. A negative change from baseline indicates worsening.	Baseline, Week 48
Change From Baseline in Letter-Number Sequencing Test at Week 48	Letter number is a test of working memory which involves ordering a series of up to 8 letters and numbers in which the numbers are repeated back first in order starting with the lowest number, then followed by the letters in alphabetical order. LNS consists of 10 items and each item has 3 trials rated as Incorrect (0) or Correct (1). The LNS total raw score (range 0 to 30) is auto-calculated by summing the 10 individual item scores (range 0 to 3 for each item). Higher number of correct items correlated to better performance and a negative change from baseline indicates worsening.	Baseline, Week 48
Change From Baseline in Color Trails at Week 48	The Color Trails test is a language free version of the Trail Making Test and was developed to allow for broader cross cultural assessment. For Part 1 (color trails test 1), the respondent uses a pencil to rapidly connect circles numbered 1-25 in sequence. For Part 2 (color trails test 2), the respondent rapidly connects number circles in sequence, but alternates between pink and yellow background. The length of time to complete each trial is recorded, along with qualitative features of performance indicative of brain dysfunction, such as near-misses, prompts, number sequence errors, and color sequence errors. Less time indicates better performance. A positive change from baseline indicates worsening.	Baseline, Week 48
Change From Baseline in Montreal Cognitive Assessment (MoCA) Score at Week 48	The MOCA was designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive function, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Scores on the MOCA range from 0-30, with higher score being better performance. A negative change from baseline indicates worsening.	Baseline, Week 48
Number of Participants With Treatment Emergent Antibodies (Anti-BIIB092) Positive Results in Serum		Up to Week 48
Change From Baseline of Brain Volumes as Determined by MRI at Week 52	A 3 dimension (3D) T1-weighted MRI was performed to estimate brain volumes (e.g., ventricles, whole brain, midbrain, pons, superior cerebellar peduncle, third ventricle, and frontal lobes).	Baseline, Week 52

Collaborators and Investigators

• Sponsor: Biogen

Publications and helpful links

General Publications

• Jaeger J, Yang L, Li Y, Castrillo-Viguera C, Haeberlein SB, Dam T, O'Gorman J. Development of a cognitive composite for measuring change in progressive supranuclear palsy. Parkinsonism Relat Disord. 2021 Nov;92:94-100. doi: 10.1016/j.parkreldis.2021.10.007. Epub 2021 Oct 12.
• Dam T, Boxer AL, Golbe LI, Hoglinger GU, Morris HR, Litvan I, Lang AE, Corvol JC, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper K, Kamisoglu K, Wald MJ, Graham DL, Gedney L, O'Gorman J, Haeberlein SB; PASSPORT Study Group. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021 Aug;27(8):1451-1457. doi: 10.1038/s41591-021-01455-x. Epub 2021 Aug 12. Erratum In: Nat Med. 2022 Oct 17;:

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2017
• Primary Completion (Actual): September 6, 2019
• Study Completion (Actual): February 7, 2020

Study Registration Dates

• First Submitted: February 27, 2017
• First Submitted That Met QC Criteria: February 27, 2017
• First Posted (Actual): March 1, 2017

Study Record Updates

• Last Update Posted (Actual): December 21, 2020
• Last Update Submitted That Met QC Criteria: November 25, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Eye Diseases; Neurologic Manifestations; Basal Ganglia Diseases; Movement Disorders; Neurodegenerative Diseases; Tauopathies; Cranial Nerve Diseases; Ocular Motility Disorders; Paralysis; Ophthalmoplegia; Supranuclear Palsy, Progressive
• Other Study ID Numbers: 251PP301; 2016-002554-21 (EudraCT Number); CN002-012 (Other Identifier: Briston-Myers Squibb)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No